Summary & Overview
HCPCS A9515: Choline C-11 Diagnostic PET Study Dose
HCPCS Level II code A9515 denotes choline C-11, a diagnostic radiopharmaceutical billed per study dose (up to 20 millicuries) used primarily in PET imaging. As an agent for molecular imaging, choline C-11 supports diagnostic evaluation of certain cancers and other metabolic processes; its use has implications for imaging workflows, supply chain for short‑half‑life radioisotopes, and payer coverage policies nationwide. Nationally, A9515 matters because it reflects reimbursement and utilization patterns for advanced PET diagnostics tied to specialized radiochemistry and time‑sensitive delivery.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The report outlines how these payers generally approach coverage for radiopharmaceuticals and imaging studies, while noting variations in prior authorization and site‑of‑service allowances.
Readers will find benchmarks on utilization and reimbursement frameworks, summaries of common billing and administrative considerations for A9515, and the clinical context for choline C-11 PET studies. The publication clarifies service settings, coding scope, and areas where policy updates or payer guidance commonly affect billing and access. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code A9515 describes Choline C-11, a diagnostic radiopharmaceutical, billed per study dose up to 20 millicuries. This code represents the supply of the radioactive tracer used for PET imaging studies that employ choline labeled with carbon-11 for diagnostic evaluation.
Service Type: Diagnostic radiopharmaceutical administration for PET imaging
Typical Site of Service: Hospital outpatient imaging departments, freestanding PET imaging centers, and academic medical centers
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 60-year-old male with biochemical evidence of recurrent prostate cancer (rising PSA) after prior prostatectomy. The clinician orders a diagnostic PET study using A9515 (Choline C-11, per study dose up to 20 millicuries) to localize recurrent or metastatic disease. The clinical workflow: the patient presents to an outpatient nuclear medicine or PET imaging center, screening and consent are obtained, IV access is established, and the radiopharmacy dispenses a patient-specific dose of Choline C-11 within the allowed activity (up to 20 mCi). The patient rests quietly to minimize muscular uptake, then receives tracer injection. After an appropriate uptake period, PET/CT imaging is performed covering the pelvis and abdomen with additional whole-body acquisition as clinically indicated. Images are reconstructed and interpreted by a nuclear medicine physician or radiologist. Final report documents tracer uptake in prostate bed, pelvic lymph nodes, or distant sites to guide further management such as targeted radiation, systemic therapy, or biopsy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier information reported | Use when no special modifier applies and payer requires default 00. |